$1.39
Revenue is up for the last 2 quarters, 83.0K → 108.0K (in $), with an average increase of 23.2% per quarter
Netprofit is up for the last 2 quarters, -11.22M → -11.15M (in $), with an average increase of 0.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 92.3%
In the last 3 years, Novo Nordisk A/s has given 162.0% return, outperforming this stock by 252.2%
5.76%
Downside
Day's Volatility :7.09%
Upside
1.42%
13.67%
Downside
52 Weeks Volatility :56.99%
Upside
50.18%
Period | Cardiff Oncology Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -5.44% | -3.0% | 0.0% |
6 Months | -15.76% | 0.5% | 0.0% |
1 Year | -9.74% | 6.3% | 6.3% |
3 Years | -90.2% | 22.1% | 17.3% |
Market Capitalization | 82.7M |
Book Value | $1.94 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.88 |
Wall Street Target Price | 7.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -10350.73% |
Return On Assets TTM | -23.31% |
Return On Equity TTM | -38.29% |
Revenue TTM | 412.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 18.7% |
Gross Profit TTM | -26.7M |
EBITDA | -42.3M |
Diluted Eps TTM | -0.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.06 |
EPS Estimate Next Year | -1.29 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.27 |
What analysts predicted
Upside of 427.34%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 505.4K | ↑ 32.63% |
Net Income | -24.9M | ↓ 36.47% |
Net Profit Margin | -4.9K% | ↑ 5359.66% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 378.3K | ↓ 25.14% |
Net Income | -16.5M | ↓ 33.91% |
Net Profit Margin | -4.4K% | ↑ 577.02% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 244.6K | ↓ 35.34% |
Net Income | -16.4M | ↓ 0.29% |
Net Profit Margin | -6.7K% | ↓ 2358.67% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 366.0K | ↑ 49.61% |
Net Income | -19.3M | ↑ 17.62% |
Net Profit Margin | -5.3K% | ↑ 1434.59% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 359.0K | ↓ 1.91% |
Net Income | -28.3M | ↑ 46.53% |
Net Profit Margin | -7.9K% | ↓ 2605.35% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 386.0K | ↑ 7.52% |
Net Income | -38.7M | ↑ 36.89% |
Net Profit Margin | -10.0K% | ↓ 2152.66% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 74.0K | ↓ 44.36% |
Net Income | -11.0M | ↑ 16.43% |
Net Profit Margin | -14.9K% | ↓ 7756.16% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 91.0K | ↑ 22.97% |
Net Income | -10.4M | ↓ 5.0% |
Net Profit Margin | -11.5K% | ↑ 3379.59% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 93.0K | ↑ 2.2% |
Net Income | -8.6M | ↓ 17.93% |
Net Profit Margin | -9.2K% | ↑ 2259.69% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 83.0K | - |
Net Income | -11.2M | ↑ 28.69% |
Net Profit Margin | -13.5K% | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 108.0K | ↑ 30.12% |
Net Income | -11.2M | ↓ 0.6% |
Net Profit Margin | -10.3K% | ↑ 3192.06% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 12.3M | ↓ 72.05% |
Total Liabilities | 5.8M | ↓ 76.1% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 14.2M | ↑ 15.36% |
Total Liabilities | 4.1M | ↓ 29.25% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 13.1M | ↓ 7.66% |
Total Liabilities | 5.8M | ↑ 41.26% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 134.7M | ↑ 929.51% |
Total Liabilities | 6.6M | ↑ 13.75% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 149.5M | ↑ 11.0% |
Total Liabilities | 9.1M | ↑ 38.93% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 116.2M | ↓ 22.3% |
Total Liabilities | 9.8M | ↑ 7.9% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 139.2M | ↓ 6.91% |
Total Liabilities | 9.1M | ↓ 0.27% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 131.3M | ↓ 5.71% |
Total Liabilities | 10.8M | ↑ 18.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 123.6M | ↓ 5.81% |
Total Liabilities | 10.4M | ↓ 3.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 116.2M | ↓ 6.02% |
Total Liabilities | 9.8M | ↓ 5.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.5M | ↓ 8.3% |
Total Liabilities | 10.0M | ↑ 2.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 97.5M | ↓ 8.54% |
Total Liabilities | 10.9M | ↑ 8.26% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.3M | ↓ 25.0% |
Investing Cash Flow | 24.0M | ↓ 196.49% |
Financing Cash Flow | -6.4M | ↓ 377.14% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.2M | ↓ 43.31% |
Investing Cash Flow | 22.8K | ↓ 99.9% |
Financing Cash Flow | 16.4M | ↓ 357.19% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.3M | ↑ 0.52% |
Investing Cash Flow | -67.6K | ↓ 396.04% |
Financing Cash Flow | 12.1M | ↓ 26.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.3M | ↑ 22.97% |
Investing Cash Flow | -211.9K | ↑ 213.33% |
Financing Cash Flow | 137.3M | ↑ 1036.95% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.0M | ↑ 41.22% |
Investing Cash Flow | -131.4M | ↑ 61938.89% |
Financing Cash Flow | 35.5M | ↓ 74.18% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.8M | ↑ 46.79% |
Investing Cash Flow | 38.1M | ↓ 129.02% |
Financing Cash Flow | 75.0K | ↓ 99.79% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.2M | ↑ 38.69% |
Investing Cash Flow | 18.4M | ↓ 308.76% |
Financing Cash Flow | 75.0K | ↓ 99.5% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.7M | ↓ 34.68% |
Investing Cash Flow | 7.6M | ↓ 58.56% |
Financing Cash Flow | 75.0K | ↑ 0.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.5M | ↑ 11.81% |
Investing Cash Flow | 5.2M | ↓ 32.14% |
Financing Cash Flow | 75.0K | ↑ 0.0% |
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cardiff Oncology Inc | -22.35% | -15.76% | -9.74% | -90.2% | -71.04% |
![]() Moderna, Inc. | -11.43% | -29.94% | -12.65% | 45.99% | 455.32% |
![]() Regeneron Pharmaceuticals, Inc. | -1.44% | 1.41% | 19.47% | 47.01% | 108.75% |
![]() Novo Nordisk A/s | -3.29% | 15.05% | 82.56% | 161.96% | 290.64% |
![]() Seagen, Inc. | 2.56% | 4.47% | 55.05% | 8.41% | 161.4% |
![]() Vertex Pharmaceuticals Incorporated | -0.86% | 11.4% | 20.1% | 27.79% | 81.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cardiff Oncology Inc | NA | NA | NA | -1.06 | -0.38 | -0.23 | 0.0 | 1.94 |
![]() Moderna, Inc. | 34.94 | 34.94 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 22.08 | 22.08 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.05 | 43.05 | 2.03 | 1.64 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.67 | 26.67 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cardiff Oncology Inc | Buy | $82.7M | -71.04% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $38.2B | 455.32% | 34.94 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 108.75% | 22.08 | 33.93% |
![]() Novo Nordisk A/s | Buy | $412.6B | 290.64% | 43.05 | 33.4% |
![]() Seagen, Inc. | Hold | $39.8B | 161.4% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $89.7B | 81.52% | 26.67 | 35.4% |
Vanguard Group Inc
BlackRock Inc
LAURION CAPITAL MANAGEMENT LP
Geode Capital Management, LLC
Renaissance Technologies Corp
GSA Capital Partners LLP
Cardiff Oncology Inc’s price-to-earnings ratio stands at None
Read Moretrovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh
Organization | Cardiff Oncology Inc |
Employees | 25 |
CEO | Dr. Mark Erlander Ph.D. |
Industry | Health Services |
Ishares Jp Morgan Em Corpora
$1.39
-2.8%
Valhi, Inc.
$1.39
-2.8%
Zim Integrated Shipping Serv
$1.39
-2.8%
Mercantile Bank Corp
$1.39
-2.8%
Lantern Pharma Inc
$1.39
-2.8%
Franklin Street Properties Corp
$1.39
-2.8%
Ars Pharmaceuticals Inc
$1.39
-2.8%
Citizens Financial Services Inc
$1.39
-2.8%
Fidelity D&d Bancorp Inc
$1.39
-2.8%